================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 7, 2007

                                MGI PHARMA, INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

    Minnesota                        0-10736                     41-1364647
- --------------------------------------------------------------------------------
 (State or other                   (Commission                (I.R.S. Employer
 jurisdiction of                   File Number)              Identification No.)
 incorporation or
 organization)


5775 West Old Shakopee Road, Suite 100, Bloomington, Minnesota          55437
- --------------------------------------------------------------------------------
(Address of principal executive offices)                              (Zip Code)




       Registrant's telephone number, including area code: (952) 346-4700


- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)
|_|  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)
|_|  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17CFR 240.14d-2(b))
|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))




                    INFORMATION TO BE INCLUDED IN THE REPORT


Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.

On February 7, 2007, MGI PHARMA, INC. issued a press release reporting financial
results for the quarter and year ended December 31, 2006. A copy of MGI PHARMA's
press release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.

Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d)     Exhibits

        99.1 MGI PHARMA, INC. press release dated February 7, 2007, announcing
             financial results for the quarter and year ended December 31, 2006.




                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                               MGI PHARMA, INC.

Date: February 7, 2007                         By: /s/ William F. Spengler
                                                  ------------------------------
                                                  William F. Spengler
                                                  Executive Vice President and
                                                  Chief Financial Officer




                                  EXHIBIT INDEX
     99.1 MGI PHARMA,  INC.  press  release dated  February 7, 2007,  announcing
          financial results for the quarter and year ended December 31, 2006.